Trump Fast-Tracks Psychedelic Therapy Research
CNBC reported Sunday that President Donald Trump has signed an executive order aimed at accelerating psychedelic therapy research for serious mental illness. The move marks a sharp reversal from his first administration’s harder line on controlled substances.
A Notable Policy Shift on Psychedelics
Trump signed the order in April, directing federal agencies to speed up clinical research into compounds like psilocybin, MDMA, and ibogaine. The White House stated these substances show genuine promise for patients who have not responded to conventional treatment. The administration simultaneously issued priority review vouchers to three companies: Compass Pathways, Usona Institute, and Transcend Therapeutics. Those vouchers are designed to accelerate portions of the FDA’s review process for their respective therapies.
Wall Street moved quickly. Shares of psychedelic drug developers rallied after the announcement. Analysts argued the executive order could legitimize a sector long dismissed as fringe science.
What the Science Actually Says
Researchers caution that enthusiasm should be tempered. Brandon Weiss, a scientist at the Center for Psychedelic and Consciousness Research at Johns Hopkins University, told CNBC that these compounds are not interchangeable. Each carries a distinct safety profile and risk level. Psilocybin has shown potential in depression studies, MDMA-assisted therapy has been studied for PTSD, and ibogaine — derived from a West African plant — has drawn attention for treating addiction and traumatic brain injuries. Despite their differences, regulators often group these treatments together because all involve supervised therapeutic sessions.
Background: A Long Road to the Mainstream
Psychedelic research existed at the margins of medicine for decades. Federal restrictions sharply curtailed serious clinical investigation following the drug crises of the 1960s and 1970s. A slow rehabilitation began in the early 2000s, led largely by academic institutions. The FDA granted psilocybin “breakthrough therapy” designation in 2018, signaling growing regulatory openness. That progress attracted venture capital and a wave of biotech startups. Trump’s executive order now injects federal momentum into a pipeline that had been advancing largely without White House support.
Patients and Investors Watch Closely
Veterans with PTSD represent one of the most cited potential patient populations. CNBC featured the account of a former Army Reserve soldier who described MDMA-assisted therapy as transformative after her deployment to Iraq. Her experience reflects a growing body of anecdotal and clinical data that advocates argue supports wider access. Critics, however, point to unresolved questions around dosing, therapist training, and long-term psychological effects. How the FDA ultimately weighs those concerns will determine whether the executive order translates into approved treatments or stalls in the review process.
Read Next: What the Fed’s Rate Path Means for Risk Assets in 2026
